SimplerQMS company claims cannot validate a buyer's eQMS

Identify the holder and scope of each assurance

The direct answer is to keep three different evidence objects: supplier management-system claims, provider validation deliverables, and the buyer's computerized-system assurance for its own intended use. SimplerQMS' official page says SimplerQMS A/S is certified to ISO 13485:2016 and ISO/IEC 27001:2022. That is a provider-controlled statement about a named legal entity; this publication has not reviewed the issuing bodies, certificate numbers, dates, accredited scope, sites, or current standing. Even an independently verified supplier certificate would not automatically certify a software module, a customer's quality management system, or a particular electronic record.

A qualification file should request the exact certificate and issuer, entity and location coverage, business processes in scope, exclusions, version and surveillance status, validation support package, supplier release-control procedure, hosting and subcontractor responsibilities, security-control evidence, support arrangements, and change notice process. Record who checked each artifact, when, how its scope relates to the contracted product, and what remains unavailable. Label a provider statement as such until the underlying document is examined.

Define the customer's regulated use before testing

SimplerQMS presents modules for documents, training, change, deviations, CAPA, complaints, design, risk, and suppliers. A medical-device design-control record, a finished-drug batch quality event, and a laboratory training record have different accountable procedures, data, signatures, review points, retention needs, and authority context. Selection begins by naming the customer's product and site, subsector, record type, intended decision, release, purchased modules, configuration, roles, interfaces, migration population, applicable procedure, and actual user population. The provider's broad life-sciences coverage does not establish those facts for one buyer.

For every intended workflow, map requirements to configuration, risk, test case, expected behavior, observed behavior, deviation, corrective retest, approval, controlled release, and ongoing monitoring. Check electronic-signature meaning, signer identity, audit-trail behavior, record export, time zone, versioning, access segregation, overwritten fields, and failed transfers under the applicable customer process. No claim that software is validated can substitute for that traceable evidence. Supplier deliverables may be useful inputs, but the customer's quality, validation, process, technology, privacy, and security owners decide what is adequate for the actual use.

Keep standard, product statement, and customer conclusion apart

The page lists support or alignment statements concerning FDA, ISO, EU GMP, data integrity, and other frameworks. Those statements should be indexed by the exact named framework, provider wording, product or module, source version, country and sector where relevant, and evidence supplied. ISO 13485 certification of the supplier company, if substantiated, is one organization-level state; FDA 21 CFR Part 11 applicability to a particular required record and electronic signature is a different question; computer software assurance guidance is not a regulator's endorsement of SimplerQMS. Do not turn a matrix of provider logos or standard names into an inspection or compliance conclusion.

Buyers should ask which claims refer to the legal entity, SaaS operating service, software design, optional content, validation documentation, implementation services, or a customer's controlled use. Preserve any claimed certifications separately from evidence of configured behavior. Request precise release history and changes to workflows, signatures, exports, retention, connectors, infrastructure, and supplier controls; decide which changes require regression testing and which historical records must remain readable. A passing supplier audit and a successful demonstration still leave regulated-use and operating-effectiveness questions open.

Test one release in two distinct life-sciences settings

Use synthetic data in a medical-device complaint-to-CAPA process and, separately, a pharmaceutical deviation-to-batch-disposition process. Change a form, signer role, rule, and integration; migrate an in-flight record; deny an unauthorized signature; generate and amend an export; then upgrade the provider release. Reviewers should reconstruct source data, configured controls, test failures, retests, approvals, deployed baseline, supplier documentation, and record access after the change. Do not transfer a result from one setting to the other or present either synthetic case as a regulatory validation of a real organization.

SimplerQMS' official page supports its attributed product-module and sector positioning and records its own statements about company certifications, validation, and regulatory support. It does not establish a currently verified accredited certificate here, certified software, a customer's license, exact release, intended use, validation, hosted control operation, data integrity, signature validity, QMSR or GMP conformance, quality outcome, inspection result, or product release decision. This article explains an evidence request for qualified owners; it is not validation, regulatory, quality, clinical, cybersecurity, certification, or legal advice.

Enterprise buyer test

Translate this change into the exact population, record type, workflow stage, decision owner, effective date, and evidence that could be affected. Ask current or prospective providers to demonstrate the named workflow with representative data and an exception—not a polished feature tour. Record what official documentation establishes, what a provider states, what the team observes, and what remains unresolved.

A defensible review also identifies the dependency outside the product. Authority interpretation, policy configuration, data quality, integrations, human judgment, approval rights, release governance, training, and retained evidence may remain customer or service responsibilities. The evaluation should preserve those boundaries instead of treating a technology claim as the complete operating model.

What we will watch next

RegQuality Review will watch the named source and affected market records for later evidence that changes status, scope, availability, implementation timing, workflow consequence, or the limits of the initial report. A later announcement does not silently overwrite this dated account; the change ledger preserves the sequence.